Tisento Therapeutics Inc.
- Address
- 245 1st Street Suite 18
Sponsor Overview
Specializations
Mitochondrial Disease Research
Tisento Therapeutics Inc. focuses on mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), with clinical activity centered on the treatment of this rare mitochondrial disorder and its neurological and systemic manifestations.
- MELAS
- Mitochondrial encephalomyopathy
- Lactic acidosis
- Stroke-like episodes
The sponsor’s research interest is directed toward clinical evaluation in patients affected by inherited energy metabolism dysfunction.
Neurological and Cognitive Symptoms
Its clinical trials examine the impact of treatment on cognition and fatigue, reflecting interest in the neurological burden associated with MELAS and related functional impairment.
- Cognition
- Fatigue
- Neurological impairment
- Functional symptoms
These areas align with the sponsor’s emphasis on symptom domains that affect daily functioning in people living with mitochondrial disease.
Safety and Tolerability
The sponsor places strong focus on safety and tolerability assessment for zagociguat, supporting ongoing clinical interest in the treatment profile of this investigational therapy in MELAS.
- Long-term safety
- Tolerability
- Investigational therapy
- Clinical monitoring
This work is directed toward understanding how the therapy is experienced over time in a rare-disease population.
Rare Disease Clinical Development
Tisento Therapeutics Inc. is active in rare disease clinical research, with studies conducted across multiple sites in North America and additional international activity, indicating a focused development program in a specialized therapeutic area.
- Rare disease therapeutics
- Multisite clinical research
- International trial activity
- Specialty neurometabolic care
The sponsor’s clinical portfolio is concentrated on a single disease area, reinforcing its interest in targeted development for mitochondrial and neurometabolic conditions.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Zagociguat in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) Patients |  Germany Italy | Not Recruiting |
| Open-Label Extension Study on Long-Term Safety of Zagociguat in MELAS Patients Post TIS6463-203 Completion | Germany Italy | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial165 other sponsors
- 2.Not possible to specify1 trial220 other sponsors
Partnered Research Centres
5 centres- Address
- Via Paradisa 2, 56124 Pisa
- Address
- Via Giacomo Venezian 1, 20133 Milan
- Address
- Largo Francesco Vito 1, 00168 Rome
- Address
- Pettenkoferstrasse 8a, Ludwigsvorstadt-Isarvorstadt, 80336 Munich
- Address
- Venusberg-Campus 1, Venusberg, 53127 Bonn
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Tisento Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.